Digital Patient and Drug Response Pipeline - Comprehensive Implementation Plan

Pipeline Overview

flowchart TB
    subgraph Patient["Patient Profile Generation"]
        A1[1. Medical Records Creation] --> A2[2. Disease-specific Genome]
        A2 --> A3[3. Disease-specific Protein Variants]
        A3 --> A4[4. Disease-specific Transcriptome]
        A4 --> A5[5. Disease-specific Proteome]
        A5 --> A6[6. Disease-specific Metabolome]
        A6 --> A7[7. Disease-specific Immunome]
    end

    subgraph Drug["Drug Analysis & Modeling"]
        B1[8. Drug-Target PK] --> B1a[8a. Binding Site Prediction]
        B1a --> B1b[8b. Drug-Target Docking]
        B1b --> B2[9. Drug-Proteome Screening]
        B2 --> B3[10. Off-target Analysis]
        B3 --> B4[11. Drug-Compound Screening]
        B4 --> B5[12. Drug-Genome Sensitivity]
    end

    subgraph Response["Response Prediction"]
        C1[13. Transcriptomic Changes] --> C2[14. Disease Stage Evaluation]
        C2 --> C3[15-16. Proteomic & Metabolomic Changes]
        C3 --> C4[17-19. Biological & Immune Response]
        C4 --> C5[20-21. ADMET & Toxicity]
    end

    Patient --> Drug
    Drug --> Response

Part 1: Digital Patient Generation

Implementation Status Overview

Step	Status	Tool/Method	Input	Output	Location	Validation Data	Dependencies/Notes
1. Medical Records	✓	Synthea	-	Demographics, records	/Workspace/next/registry/tools/synthea	Target: 1000 patients/disease	-
2. Disease Genome	✓	Omic-UKBB	Alleles, positions, frequencies	VCF (hg38)	Part of Synthea repo	-	Only storing variants
3. Protein Variants	✓	vcf2prot	VCF	Protein fasta	Part of Synthea repo (tbc)	-	Multi-tissue support needed
4. Transcriptome	🚧	borzoi	Genomic sequences	RNAseq (TPM)	-	ENCODE, GTEx (E-MTAB-6814)	NIH ENCODE standards
5. Proteome	🚧	clei2block	RNAseq (log2-FC)	Fold-change	github.com/stasaki/clei2block	CellModelPassport, TCGA	Requires GTEx training
6. Metabolome	⏳	corto	RNAseq (TPM)	Metabolite profiles	github.com/federicogiorgi/corto	CCLE, NCI-60	-
7. Immunome	⏳	Ecotyper	RNAseq	Cell type profiles	-	SPICA30, SPICA17	-

Active Implementation Tasks

Transcriptome Generation

Current goal: Establish accurate transcriptome prediction pipeline

• Implement and evaluate primary models:
  • enformer
  • basenji
  • borzoi for RNAseq profiles, built on basenji and enformer
• Add SequenceModelBenchmark ridge regression - built into borzoi (tbc)
• Validate against ENCODE standards
• Implement GTEx validation pipeline

Multi-omic Integration

Current goal: Create robust data transformation pipeline

• Proteome prediction (clei2block):
  • Implement GTEx training pipeline
  • Add multi-tissue support
  • Create validation framework against CellModelPassport
• Metabolome generation (corto):
  • Setup CCLE data integration
  • Implement NCI-60 validation
• Immunome profiling:
  • Evaluate Ecotyper vs CIBERTSORTx CIBERTSORTx incorporated within Ecotyper
  • Integrate SPICA datasets
  • Setup immune cell validation pipeline

Part 2: Drug Discovery and Response

Drug Development Tools

Current goal: Establish comprehensive drug analysis pipeline

• Molecule Processing:
  • SELFIES library for biologics/peptides conversion
  • Implement molecule validation checks
  • Setup standardization pipeline
• Structure Analysis:
  • DreamDock + ConPlex score pipeline
  • LightDock for membrane binding
  • Validation framework with crystal structures

Binding Site Prediction

Current goal: Create consensus model for binding site prediction

• Benchmark tools:
  • DiffDock implementation and testing
  • Qvina2 evaluation
  • P2Rank integration
  • FPocket analysis
• Specific considerations:
  • Allosteric site detection
  • Multiple binding site handling
  • Protein flexibility modeling
• Validation:
  • BindingDB integration
  • Crystal structure comparison pipeline
  • Edge case testing suite

Drug-Target Analysis

Current goal: Robust docking and interaction prediction

• Primary docking pipeline:
  • Uni-mol integration
  • DreamDock implementation
  • Path4Drug integration for pathways
• Molecule type-specific handling:
  • Small molecule pipeline
  • Biologics pathway
  • PROTACs specific analysis
  • Prodrug processing
• Interaction analysis:
  • Agonist vs antagonist classification
  • Protein-protein interaction integration
  • Chemical_checker for bioactivity signatures

Chemical Property Prediction

Current goal: Comprehensive property prediction system

• Model implementation:
  • Chemprop evaluation
  • Soltrannet integration
  • Custom ADMET model development
• Property coverage:
  • Solubility prediction
  • BBB penetration
  • Chemical stability
  • Metabolic processing

Toxicity Prediction Pipeline

Current goal: Multi-faceted toxicity assessment system

• Core modules:
  • Cardiotoxicity (ion channel) prediction
  • Hepatotoxicity (Phase 1/2 proteins)
  • Nephrotoxicity assessment
  • Lung toxicity prediction
  • Neurotoxicity (BBB criteria)
  • Inflammatory response modeling
  • Bleeding/clotting risk analysis
• Integration components:
  • Human Protein Atlas tissue proportion estimation
  • Reactome pathway analysis
  • Industry model benchmarking

Drug Response Analysis

Current goal: Integrated response prediction system

• Transcriptomic response:
  • LINCS data integration
  • Expression change prediction
  • Tissue-specific effects
• Multi-omic response:
  • Proteomic change modeling
  • Metabolomic adjustment prediction
  • Immune response profiling
• Special cases:
  • Multi-drug combinations
  • Time-dependent effects
  • Population-specific responses

Critical Dependencies & Requirements

Category	Component	Status	Notes
External Data	BindingDB	✓ Available	Binding affinities
	LINCS	✓ Available	Compound effects
	PharmGKB	⏳ Pending	Variant annotations
	Human Cell Atlas	⏳ Pending	Tissue-specific data
Compute	GPU Cluster	🚧 Scaling	For enformer/basenji
	Storage	✓ Configured	For variant data
	Distribution	⏳ Planned	For processing

Validation Framework

Dataset	Usage	Status	Notes
ENCODE	Transcriptomics	✓ Ready	Primary validation
GTEx	Tissue-specific	✓ Ready	E-MTAB-6814
CCLE/GDSC2	Cell lines	🚧 In Progress	Cancer validation
TDC	ADMET	⏳ Planned	Benchmark data
Cross-species	Conservation	⏳ Planned	Evolutionary validation
Time-series	Metabolics	⏳ Planned	Kinetic validation

Edge Cases & Special Considerations

Complex Scenarios

Scenario	Implementation Status	Handling Strategy
Rare variants	🚧 In Progress	Population frequency weighting
Multi-drug combinations	⏳ Planned	Interaction matrix modeling
Time-dependent effects	⏳ Planned	PK/PD time series modeling
Population specificity	🚧 In Progress	Demographic stratification

Special Drug Classes

Class	Special Requirements	Status
Biologics	Membrane modeling, immunogenicity	⏳ Planned
Prodrugs	Metabolite prediction, activation	🚧 In Progress
Combination therapy	Interaction prediction, timing	⏳ Planned
PROTACs	Protein degradation modeling	⏳ Planned

Case Studies & Validation Examples

Drug	Outcome	Learning Points	Implementation Status
Amcenestrant	Efficacy failure	Target validation importance	✓ Integrated
Flupirtine	Liver toxicity	Metabolite prediction crucial	🚧 In Progress
Ranitidine	NDMA formation	Chemical stability prediction	⏳ Planned
Multi-drug Examples	Variable	Interaction modeling needed	⏳ Planned